The 2014 Ebola epidemic prompted an urgent need for an approved vaccine to treat or prevent the disease in future outbreaks. Based on Battelle’s extensive experience in vaccine testing and managing highly regulated, complex projects involving high-containment pathogens, we were chosen to evaluate the immunogenicity and efficacy of Ebola vaccine candidates to determine if they were protective.
Battelle leveraged experience developing surrogate models of disease to work with multiple partner BSL-4 labs to evaluate the vaccines’ efficacy.
Researchers developed novel assays and readouts including:
- ELISA for serum samples to determine the concentration of antibody binding the desired pathogen
- Pseudovirion neutralization assay to test for neutralizing serum antibody
- Flow-cytometry-based assay that examines the cell activation, cytokines releases and other markers of cell activation to determine if activation of a certain population correlates with effectiveness of vaccine and regimen